Van Lanschot Kempen Investment Management N.V. Takes $135.49 Million Position in Icon Plc $ICLR

Van Lanschot Kempen Investment Management N.V. bought a new stake in shares of Icon Plc (NASDAQ:ICLR) during the 4th quarter, Holdings Channel.com reports. The institutional investor bought 743,548 shares of the medical research company’s stock, valued at approximately $135,489,000. Icon accounts for 1.2% of Van Lanschot Kempen Investment Management N.V.’s holdings, making the stock its 24th largest position.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ICLR. WINTON GROUP Ltd bought a new stake in Icon during the 2nd quarter valued at approximately $254,000. Daiwa Securities Group Inc. raised its stake in Icon by 19.3% during the 2nd quarter. Daiwa Securities Group Inc. now owns 28,145 shares of the medical research company’s stock valued at $4,094,000 after purchasing an additional 4,546 shares during the period. Frontier Capital Management Co. LLC raised its stake in Icon by 97.6% during the 2nd quarter. Frontier Capital Management Co. LLC now owns 71,360 shares of the medical research company’s stock valued at $10,379,000 after purchasing an additional 35,253 shares during the period. Peapack Gladstone Financial Corp bought a new stake in Icon during the 2nd quarter valued at approximately $212,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Icon by 58.7% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 781 shares of the medical research company’s stock valued at $113,000 after purchasing an additional 289 shares during the period. Institutional investors own 95.61% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Rothschild & Co Redburn set a $100.00 target price on Icon and gave the company a “neutral” rating in a research note on Tuesday, February 17th. Robert W. Baird set a $119.00 target price on Icon in a research note on Friday, February 13th. JPMorgan Chase & Co. lifted their target price on Icon from $120.00 to $130.00 and gave the company a “neutral” rating in a research note on Friday, May 29th. Citigroup lifted their target price on Icon from $120.00 to $140.00 and gave the company a “neutral” rating in a research note on Friday, May 29th. Finally, Truist Financial lifted their target price on Icon from $139.00 to $159.00 and gave the company a “hold” rating in a research note on Friday, May 29th. Eight analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Icon currently has a consensus rating of “Hold” and an average target price of $156.44.

Icon Stock Performance

NASDAQ ICLR opened at $146.18 on Friday. The company has a market cap of $11.19 billion, a P/E ratio of 23.73, a P/E/G ratio of 11.84 and a beta of 1.26. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.10 and a current ratio of 1.10. The business’s 50 day moving average price is $121.76 and its 200-day moving average price is $140.47. Icon Plc has a fifty-two week low of $66.57 and a fifty-two week high of $211.00.

Icon (NASDAQ:ICLR) last released its earnings results on Wednesday, June 17th. The medical research company reported $2.52 earnings per share for the quarter, beating the consensus estimate of $2.47 by $0.05. The firm had revenue of $2.11 billion for the quarter, compared to the consensus estimate of $1.99 billion. Icon had a return on equity of 9.50% and a net margin of 5.98%.The company’s revenue for the quarter was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.43 EPS. Sell-side analysts predict that Icon Plc will post 9.74 earnings per share for the current year.

Icon Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.